Indian pharmaceutical company Natco Pharma Limited has signed a nonexclusive, royalty free licensing agreement with the Medicines Patent Pool and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol-Myer Squibb’s chronic hepatitis C medicine – Daclatasvir Dihydrochloride.
Daclatasvir is used to treat hepatitis C virus genotype 3 patients.
Natco will market generic Daclatasvir under its own brand, NATDAC, and through its strategic partners in India.
Natco to sell NATDAC in 112 developing countries
Natco noted in its press release on Thursday that this agreement will allow it to expand access to the chronic hepatitis C medicines in 112 developing countries.
Under the license, Natco says, it can sell the product for its own set price for the generics it produces.